Claims for Patent: 10,201,544

Summary for Patent: 10,201,544

Title:	Method of synthesising ADCs using affinity resins
Abstract:	This invention relates to a solid phase method of synthesizing biomolecule-drug conjugates. In particular, this invention relates to a solid phase method of synthesizing antibody-drug conjugates (ADCs). This invention also relates to intermediate methods of producing immobilized, chemically modified biomolecules, e.g. antibodies. The invention also relates to various uses of capture resins and to biomolecule-drug conjugates, intermediate products and compositions prepared by the methods of the invention.
Inventor(s):	Evans; David J. (Chester, GB), McKee; Colin M. (Conwy, GB)
Assignee:	ADC Biotechnology Ltd. (St. Asaph, GB)
Application Number:	14/786,387
Patent Claims:	1. A method of synthesising a biomolecule-drug-conjugate, the method comprising: (i) contacting a biomolecule with FAbsorbent F1P HF resin, MAbsorbent A1P resin, MAbsorbent A2P resin, or a capture resin comprising a capture moiety for the biomolecule, wherein the capture moiety is: a branched ligand scaffold of formula: ##STR00010## wherein R.sup.1 and R.sup.2 are the same or different and are each optionally substituted alkyl or aryl ligands, and R.sup.3 is a solid support optionally attached by a spacer motif; or a branched triazyl scaffold of formula: ##STR00011## wherein Q represents the attachment point to a solid support matrix, optionally with a spacer motif and Groups A and B are phenyl or naphthyl groups substituted with one or more substituents capable of hydrogen bonding, optionally one or more of --OH, --SH and --CO.sub.2H; under conditions suitable to immobilise the biomolecule and therefore provide an immobilised biomolecule; wherein the biomolecule is an antibody, modified antibody or antibody fragment; (ii) optionally contacting the immobilised biomolecule with a chemical modification agent or activating agent to provide a chemically modified or activated, immobilised biomolecule; (iii) contacting the immobilised biomolecule or the chemically modified or activated, immobilised biomolecule with a drug component to form an immobilised biomolecule-drug-conjugate; and (iv) releasing the biomolecule-drug-conjugate from the capture resin. 2. The method of claim 1, wherein step (i) comprises incubating the biomolecule with the capture resin. 3. The method of claim 2, wherein the incubation is carried out at temperature of from about 10 to about 40.degree. C., optionally from about 15 to about 37.degree. C. 4. The method of claim 2, wherein the incubation is carried out for a period of time of about 10 minutes to about 18 hours. 5. The method of claim 2, wherein the incubation is carried out in a buffer solution, optionally phosphate buffered saline (PBS). 6. The method of claim 2, wherein the incubation is carried out at a pH of about 5 to about 8. 7. The method of claim 1, wherein after step (i) the immobilised biomolecule is washed to remove any biomolecule that has not been immobilised on the capture resin. 8. The method of claim 1, wherein step (ii) involves reducing the biomolecule. 9. The method of claim 8, wherein the biomolecule is reduced by contacting it with a reducing agent, optionally wherein the reducing agent is selected from the group consisting of tris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT), and merceptoethylamine. 10. The method of claim 1, wherein step (ii) involves reacting the biomolecule with a crosslinker moiety, optionally wherein the crosslinker moiety is succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC). 11. The method of claim 8, wherein step (ii) is carried out in a buffer solution, optionally wherein the buffer is phosphate buffered saline (PBS). 12. The method of claim 8, wherein step (ii) is carried out at a pH of about 7 to about 8. 13. The method of claim 8, wherein step (ii) is carried out in the presence of a chelating agent, optionally wherein the chelating agent is EDTA. 14. The method of claim 8, wherein step (ii) involves incubating the biomolecule with the reducing agent for a period of time of about 6 hours to about 18 hours. 15. The method of claim 1, wherein after step (ii) the activated, immobilised biomolecule is washed to remove any modification/activating agent. 16. The method of claim 1, wherein step (iii) involves contacting the chemically modified or activated, immobilised biomolecule with a drug component in a buffer solution. 17. The method of claim 1, wherein step (iii) involves contacting the chemically modified or activated, immobilised biomolecule with a drug component at a pH of about 7 to about 8, optionally at a pH of about 7.4. 18. The method of claim 1, wherein step (iii) is carried out in the presence of a chelating agent, optionally wherein the chelating agent is EDTA. 19. The method of claim 1, wherein step (iii) involves incubating the chemically modified or activated, immobilised biomolecule with drug component for a period of time of about 6 hours to about 18 hours. 20. The method of claim 1, wherein after step (iii) the immobilised biomolecule-drug-conjugate is washed to remove any unreacted drug component. 21. The method of claim 1, wherein step (iv) involves altering the pH to break the support-biomolecule bond. 22. The method of claim 21, wherein the pH is decreased to less than about pH 5, optionally about pH 3. 23. The method of claim 21, wherein the eluted biomolecule-drug-conjugate is neutralised after the step of releasing the conjugate from the capture resin, optionally the conjugate is captured into 2% v/v of 1M tris(hydroxymethyl)aminoethane (TRIS). 24. The method of claim 1, wherein the ligand of the capture resin is represented by: ##STR00012## 25. The method of claim 1, wherein the biomolecule is an antibody, optionally wherein the antibody is a monoclonal antibody and/or wherein the antibody is trastuzumab. 26. The method of claim 1, wherein the drug is a tubulin inhibitor or a DNA interacting agent; optionally wherein the tubulin inhibitor is selected from the group consisting of: (a) an auristatin; and (b) a maytansine derivative; optionally wherein the DNA interacting agent is selected from the group consisting of: (a) calicheamicins, (b) duocarmycins and (c) pyrrolobenzodiazepines (PBDs).

Details for Patent 10,201,544

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2033-04-26
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2033-04-26
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2033-04-26